Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023, and is expected to increase a significant CAGR by 2034, estimates DelveInsight
Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook
Key Takeaways from the Postpartum Depression Market Report
In May 2025, Nanjing Minova Pharmaceutical Co., Ltd. announced a study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine： To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules.
In May 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023.
In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2034.
Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market.
Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023
Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2034.
The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Stay ahead in the Postpartum Depression Therapeutics Market with DelveInsight's Strategic Report @ Postpartum Depression Treatment Market
Postpartum Depression Epidemiology
Total Diagnosed Prevalent Population of Maternal Postpartum Depression
Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence
Postpartum Depression Marketed Therapies
ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
ZULRESSO: Sage Therapeutics
ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.
Postpartum Depression Emerging Therapies
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.
To learn more about Postpartum Depression Treatment guidelines, visit @ Postpartum Depression Clinical Trials Assessment
Postpartum Depression Market Outlook
Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.
Postpartum Depression Treatment Landscape
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.
Scope of the Postpartum Depression Market Report
Coverage- 7MM
Study Period- 2020-2034
Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
Postpartum Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. Report Introduction
3. Postpartum Depression Market Overview at a Glance
4 Executive Summary of Postpartum Depression
5 Key events
6 Disease Background and Overview
7 Treatment and Management
8 Methodology
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Postpartum Depression (PPD): Seven Major Market Analysis
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Psychedelic Pharma Stock Surges on FDA Breakthrough
The psychedelic pharmaceutical sector continues gaining mainstream acceptance as regulatory barriers fall and medical applications expand beyond traditional treatments. With mental health disorders reaching epidemic proportions and conventional therapies showing limited efficacy for many patients, regulators are increasingly open to alternative treatments that were once considered fringe. This paradigm shift has created significant opportunities for companies positioned at the intersection of established pharmaceutical development and emerging psychedelic therapeutics. Shares of PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) are moving higher in Monday afternoon trading following the announcement that the company received FDA approval for its ketamine product, KETARx™, on August 8th for surgical pain management applications. This milestone represents a significant breakthrough for the specialty pharmaceutical company focused on unlocking ketamine's therapeutic potential across multiple medical conditions. The FDA approval positions PharmaTher to capitalize on the rapidly expanding ketamine market, which is currently valued at $750 million and projected to reach $3.42 billion by 2034, representing a compound annual growth rate of 16.4%. Ketamine stands out among psychedelic compounds as the only one included on the World Health Organization's Model List of Essential Medicines, providing additional validation for its therapeutic applications. The approval comes at an opportune time, as ketamine has been regularly listed on the FDA drug shortage list since February 2018, highlighting significant supply challenges in the market. The FDA has also issued compounding risk alerts regarding potential safety issues with non-approved ketamine products, creating demand for high-quality, FDA-approved alternatives like KETARx™. PharmaTher's FDA approval provides a strong foundation for expanding ketamine development across diverse therapeutic areas within the company's pipeline, including mental health conditions like depression, neurological disorders such as Parkinson's disease and ALS, and chronic pain management including Complex Regional Pain Syndrome. The market potential is demonstrated by SPRAVATO (esketamine), an FDA-approved depression treatment currently tracking a $1.6 billion sales run rate with guidance projecting $3 billion to $3.5 billion by 2027-2028. Additionally, the Veterans Health Administration currently approves and funds ketamine infusions for retired military personnel with depression, PTSD, and chronic pain, indicating established institutional acceptance. "Today marks a new chapter for PharmaTher," commented CEO Fabio Chianelli. "With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth." U.S. shares of PHRRF are up 8.6% at $0.39, while Canadian shares of PHRM are ahead 8.0% at C$0.54 in Monday afternoon trading. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
National Post
4 hours ago
- National Post
Modern Health Welcomes New Chief Technology Officer and General Counsel
Article content New Data from Modern Health Reinforces Proven Model and Offers Fresh Insight into Evolving Workforce Needs Article content SAN FRANCISCO — Modern Health, a leading global workplace mental health platform, today announced the appointments of Chen Cheng as Chief Technology Officer and Erin Brown as General Counsel, along with other company momentum, as it accelerates its mission to make mental health care more accessible, personalized, and effective worldwide. Article content In her role as Chief Technology Officer, Chen Cheng will oversee the company's technology and further scale the platform to provide high-quality, clinically rigorous care across the globe. She brings more than a decade of experience in the health technology sector to Modern Health, including roles at Oscar Health and ZocDoc. As technology plays an increasingly critical role in expanding access to mental health care and support, evidenced by the growing engagement with virtual therapy, coaching, and digital tools, Chen will leverage her tech experience and leadership to help Modern Health advance its innovations. Article content Erin Brown joins Modern Health as General Counsel, bringing more than 20 years of legal experience across the health and benefits space. Brown has amassed a proven track record of guiding high-growth organizations through complex legal and regulatory environments. Prior to Modern Health, Brown was Senior Vice President and Associate General Counsel at Alight Solutions and, before that, Associate General Counsel at Aon Hewitt. Her expertise and strategic counsel will be key as Modern Health continues to expand its global footprint and innovate responsibly in a rapidly evolving industry. Article content 'Welcoming exceptional leaders like Chen and Erin marks an exciting step forward for Modern Health,' said Matt Levin, CEO of Modern Health. 'They each bring a powerful combination of industry expertise and a passion for making mental health care more accessible, personalized, and effective. Their leadership will accelerate our momentum as we scale our impact, drive innovation, and continue delivering meaningful outcomes for the workplaces we support worldwide.' Article content In addition to these appointments, other recent company momentum includes: Article content Modern Health has been named to the 2025 Inc. 5000 list of the fastest-growing private companies in America. The list highlights companies that have demonstrated significant revenue growth over a three-year period and serves as a benchmark for entrepreneurial success and a platform for recognizing the contributions of these businesses to the US economy. Modern Health launches ROI Study that proves mental health care pays off: According to a third-party analysis of 13,000+ members, the most significant savings (60% of total savings) in health care spend for employers come from reaching more employees earlier with support that fits their needs before symptoms escalate. Modern Health's evidence-based Adaptive Care Model delivers an estimated $2.39 return for every dollar invested, based solely on health care cost savings. These compelling findings underscore how Modern Health's Adaptive Care Model improves outcomes and drives down costs by supporting the whole workforce—not just those with severe mental health concerns. Peer-reviewed data shows Modern Health's global mental health model works anywhere: In one of the largest and most diverse real-world studies of its kind, Modern Health examined engagement and clinical outcomes among more than 33,000 members across seven global regions to understand not only how mental health needs vary across regions but also whether a single care model could truly work at a global scale. The study proves that achieving global scale requires more than a one-size-fits-all approach; it demands an adaptive, evidence-based model designed to deliver meaningful results across diverse regions and populations. Modern Health's latest study paints a stark picture of how Gen Z and Millennial employees are faring: In a study of 1,000 American professionals aged 18 to 44, the findings reveal a generation silently struggling under the weight of burnout, financial anxiety, and workplace systems that haven't kept pace with their needs. Among the most striking statistics: 75% blame financial stress for fueling burnout and hurting productivity, 79% sacrifice mental health to meet work demands, and 96% want access to preventative mental health support. The workplace report highlights a troubling reality: too many young workers are quietly pushing through mounting mental health challenges just to keep up at work, underscoring the urgent need to meet people earlier, with care that's proactive, adaptive, and designed to support the mental health of entire workforce populations. Launch of FlexEAP Challenges Outdated Employee Assistance Programs: Modern Health recently launched FlexEAP ('Flex'), a next-gen Employee Assistance Program (EAP) addressing the critical shortcomings of traditional EAPs by delivering rapid access to care, adaptive support extending far beyond crisis intervention, and a seamless, consistent global experience. The product combines Modern Health's Adaptive Care Model with an elite, global provider network to deliver a seamless, personalized mental health experience. Employees can access care, on average, within 24 hours, with fast, frictionless support across therapy, coaching, crisis intervention, and digital self-guided tools. Flex delivers superior outcomes and an upgraded, consumer-grade experience compared to traditional EAPs, while offering flexible pricing, customizable solutions, and risk-sharing based on utilization—empowering employers to better manage costs. Expanded Languages for Pathways: Modern Health is proud to offer its Pathways Collections, offering tailored one-on-one support around a variety of topics, including Workplace Well-being, Family Care, and Physical Well-Being, as a truly multilingual product. Now, members can connect with a Pathway Provider in six additional languages — Spanish, Dutch, Hindi, Portuguese, Japanese, and French. Article content About Modern Health Article content Modern Health is a global leader in adaptive mental health care, dynamically offering multi-modal mental health support that delivers meaningful outcomes at a sustainable, predictable cost. With therapy, psychiatry, coaching, community groups, self-guided tools, and crisis support, we dynamically create individualized care journeys to address a spectrum of mental health needs and preferences with culturally responsive providers in 200+ countries and territories and 80+ languages. Backed by peer-reviewed research and a proprietary blend of technology and live support, Modern Health delivers measurable outcomes, globally equitable access, and sustainable pricing. Our industry-leading Adaptive Care Model and dedicated, human centered, operationally tuned, customer success partners make us a trusted partner for organizations worldwide. Article content Article content Article content Article content Article content
National Post
6 hours ago
- National Post
Japan boxing to adopt stricter safety rules after deaths of two fighters
Japanese boxing officials said on Tuesday they would introduce urine tests, stricter rules on weight loss to prevent dehydration and improve medical cover at bouts following the deaths of two fighters. Article content The new measures were adopted during an emergency meeting of the Japan Pro Boxing Association (JPBA), the Japan Boxing Commission (JBC) and gym owners on Tuesday. Article content Article content It was convened after super featherweight Shigetoshi Kotari and lightweight Hiromasa Urakawa, both 28, died days after brain surgery on injuries they sustained in separate bouts at Tokyo's Korakuen Hall on August 2. Article content The exact cause of the boxers' deaths is to be determined, but dehydration caused by cutting weight rapidly is regarded as a factor in making the brain more susceptible to bleeding, according to the World Boxing Association. Article content The deaths were 'really regrettable,' said JPBA president Shoji Kobayashi. 'We gathered today to establish a plan towards zero accidents.' Article content New measures to be implemented as soon as possible include urine tests for measuring dehydration and stricter rules on boxers' rapid weight loss, said Tsuyoshi Yasukochi, secretary-general of the JBC. Article content Ambulances will also be required on site, even for non-world championship bouts. They will partner with hospitals that are equipped to perform emergency surgery for head and other injuries. Article content Article content There will also be new rules on how long before a fight sparring must be stopped during training, he said. Article content Officials decided 'to take all measures possible so we do not let the deaths of the two be in vain,' Yasukochi added. Article content Kotari collapsed and later died after going 12 rounds in an Oriental and Pacific Boxing Federation title fight. The JBC had already announced all future OPBF title bouts would be reduced to 10 rounds. Article content 'That such an incident occurred involving top-level boxers means we may face arguments that boxing should be halted,' admitted Toshiharu Kayama, former Japan welterweight champion and president of the boxing gym Ebisu K's Box. Article content 'We, the association and gyms, want to think and change' the way the sport is contested, Kayama said. Article content An accident investigation committee will work to find out the cause of the boxers' deaths later this month and guidance on prevention measures will be updated, Yasukochi said. Article content
